GIS:FRA
Gilead Sciences
134,00 €
arrow_downward
-1,15%(-1,56) 1 d.
13. 10., 22:00:00 GMT+2 · EUR
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre GIS…
Otvoriť
134,00 €
Vysoká
134,00 €
Nízka
134,00 €
Trh. kap.
183,41 mld.
Priem. obj.
386,00
Objem
0,00
Max. za 52 týž.
134,58 €
Min. za 52 týž.
97,79 €
Počet zamestnancov
17 tis.
Otvoriť
134,00 €
Vysoká
134,00 €
Nízka
134,00 €
Trh. kap.
183,41 mld.
Priem. obj.
386,00
Objem
0,00
Max. za 52 týž.
134,58 €
Min. za 52 týž.
97,79 €
Počet zamestnancov
17 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
ad-hoc-news.de
·
pred 7 hodinami
BofA raises target for Gilead Sciences stock to USD 164.00
MarketBeat
·
pred 8 hodinami
Erste Group Bank Comments on Gilead Sciences FY2027 Earnings
ad-hoc-news.de
·
pred 15 hodinami
Gilead Sciences stock loses 0.04 percent pre-market to EUR 134.45
Insider Monkey
·
pred 21 hodinami
Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?
Profil
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Informácie o subjekte Gilead Sciences
Generálny riaditeľDaniel O'Day
Zamestnanci17 tis.
Dátum založenia22. 6. 1987
Hlavné sídloFoster City, Kalifornia, Spojené štáty americké
Odvetvie-
Webgilead.com